Alcidion Group Ltd
ASX:ALC

Watchlist Manager
Alcidion Group Ltd Logo
Alcidion Group Ltd
ASX:ALC
Watchlist
Price: 0.105 AUD Market Closed
Market Cap: 141m AUD

Alcidion Group Ltd
Investor Relations

Alcidion Group Ltd. provides intelligent health informatics technology that empowers healthcare professionals with clinical decision support systems to ensure the quality of care for the patients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The company is engaged in development, licensing and reselling its healthcare software products through its strategic partners. The company also delivers product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in Australia, New Zealand and the United Kingdom. The Company’s healthcare software products include Miya, Patientrack, Smartpage and ExtraMed. Miya Precision is a clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. Smartpage is a smartphone and Web-based system for hospital communication and task management provides solution to both clinical and non-clinical users. Patientrack is a solution that supports the capture of that data at the bedside, whether directly entered on a tablet or integrated from patient monitors. Its clinical solutions use digital technology.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Oct 27, 2025
AI Summary
Q1 2026

Strongest Q1 in Years: Alcidion delivered its best Q1 for new sales in three years ($8.2 million TCV), and for cash receipts ($8.4 million) in two years, signaling robust momentum.

Mizaic Partnership: The company expanded its key North Cumbria EPR contract with a $6.8 million addition through a partnership with Mizaic, expected to contribute approximately $1.7 million to FY '26 revenue.

Recurring Revenue Strength: 92% of new sales in the quarter were recurring product revenue, supporting a stable business model.

Operating Cash Outflow Improvement: Operating cash outflow shrank to $600,000, a major improvement from nearly $4 million in the prior year’s Q1.

Cash Position and No Debt: Alcidion ended the quarter with $16.4 million in cash and no debt.

FY '26 Guidance Reaffirmed: Management reaffirmed guidance for positive EBITDA and operating cash flow in FY '26.

Strategic Progress: The company is making headway with customer deployments and exploring new market opportunities in Saudi Arabia and Canada.

Key Financials
New Sales
$8.2 million
Cash Receipts from Customers
$8.4 million
Operating Cash Outflow
$600,000
Contracted Revenue
$36.3 million
Cash in Bank
$16.4 million
North Cumbria EPR Contract TCV
Over $45 million (10-year period)
Mizaic Partnership Revenue Contribution
$1.7 million (FY '26)
Earnings Call Recording
Other Earnings Calls

Management

Ms. Kate Quirke
Group MD, CEO & Executive Director
No Bio Available
Mr. Matthew Gepp
Chief Financial Officer
No Bio Available
Ms. Julia Stevens
Chief Operating Officer
No Bio Available
Mr. Vivek Krishnan
Chief Technology Officer
No Bio Available
Kerstin Wahlqvist
Investor Relations Manager
No Bio Available
Ms. Maria Hunter
Group General Counsel
No Bio Available
Mr. Nick White
Chief Marketing Officer
No Bio Available
Ms. Tracey Harvey
Human Resources Manager
No Bio Available
Ms. Kaye Hocking
Chief Product Officer
No Bio Available
Ms. Amanda James
Chief People Officer
No Bio Available

Contacts

Address
VICTORIA
Melbourne
L 10 9 Yarra Street, South Yarra
Contacts
+61800767873.0
www.alcidion.com